These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 4991543)

  • 1. [Pharmacology and pharmacodynamics of a hypoglycemic sulfonamide very active on insulin secretion and the neogenesis of beta cells of pancreatic Langerhans islets].
    Loubatières A; Mariani MM; Ribes G
    C R Acad Hebd Seances Acad Sci D; 1970 Oct; 271(16):1446-7. PubMed ID: 4991543
    [No Abstract]   [Full Text] [Related]  

  • 2. [A new particularly active hypoglycemic sulfonamide, HB 419 (glibenclamide)].
    Loubatières A; Mariani MM; Alric R; Capal J; Ribes G; de Malbosc H
    Diabete; 1968 Sep; ():Suppl:79-86. PubMed ID: 4924253
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmacological comparison between tolbutamide and two second generation hypoglycemic sulfonylureas (glibenclamide and glisoxepide)].
    Loubatières A; Ribes G; Mariani MM; Alric R
    Acta Diabetol Lat; 1973; 10(2):261-82. PubMed ID: 4200420
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacological studies of a new highly effective blood sugar decreasing sulfonamide, glibenclamide (HB 419)].
    Loubatières A; Mariani MM; Ribes G; de Malbosc H; Alric R; Chapal J
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1354-63. PubMed ID: 4899083
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experimental study on glibenclamide (HB 419), a new particularly active hypoglycaemic sulphonamide. II. Betacytotrophic action and stimulation of the neogenesis of the islets of Langerhans].
    Loubatières A; Mariani MM; Alric R; Ribes G; de Malbosc H; Houareau MH
    Diabetologia; 1969 Aug; 5(4):219-27. PubMed ID: 4902718
    [No Abstract]   [Full Text] [Related]  

  • 6. [Physiological and pharmacological aspects of the central role of the pancreas in the mode of action of hypoglycemic sulfonamides].
    Loubatières A
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():216-55. PubMed ID: 4906020
    [No Abstract]   [Full Text] [Related]  

  • 7. [The discovery of hypoglycemic sulfonamides and particularly of their action mechanism].
    Loubatières A
    Acta Diabetol Lat; 1969 Sep; 6 Suppl 1():20-56. PubMed ID: 4906982
    [No Abstract]   [Full Text] [Related]  

  • 8. Beta-adrenergic stimulation and insulin release in dogs following HB 419.
    Sirek OV; Vigas M; Niki A; Niki H; Sirek A
    Diabetologia; 1969 Aug; 5(4):207-10. PubMed ID: 4902716
    [No Abstract]   [Full Text] [Related]  

  • 9. [Hypoglycemic sulfonamides].
    Loubatières AL
    Actual Pharmacol (Paris); 1968; 21():173-90. PubMed ID: 4888764
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experimental study of a new especially active hypoglycemic sulfonamide, HB-419 or Glibenclamide].
    Loubatières A; Mariani MM; Ribes G; de Malbosc H; Chapal J
    Diabetologia; 1969 Feb; 5(1):1-10. PubMed ID: 4907149
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of the oral hypoglycemic agent pirogliride tartrate on insulin and glucagon secretion in vivo and in vitro.
    Tutwiler GJ; Fawthrop HC; Krill RT; Pek S
    Adv Exp Med Biol; 1979; 119():435-41. PubMed ID: 386729
    [No Abstract]   [Full Text] [Related]  

  • 12. Complementary arguments in favor of the betacytotrophic action of the hypglycemic sulfonamides.
    Loubatières AL
    Adv Metab Disord; 1970; 1():Suppl 1:411+. PubMed ID: 4911189
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effect of glycemia level on insulin secretion caused by an hypoglycemic sulfamide (glisoxepide) in dogs].
    Loubatières AL; Ribes G; Loubatières-Mariani MM
    C R Seances Soc Biol Fil; 1972; 166(8):1047-50. PubMed ID: 4573746
    [No Abstract]   [Full Text] [Related]  

  • 14. [Propranolol and hypoglycemic sulfonamides. Study on insulin secretion and blood sugar].
    Loubathières A; Mariani MM; Ribes G; Chapal J
    C R Seances Soc Biol Fil; 1971; 165(6):1393-7. PubMed ID: 4262051
    [No Abstract]   [Full Text] [Related]  

  • 15. [A morphological study on the mechanism of insulin-release, using sulfonylurea, l-leucine, and alpha-ketocarboxylic acids].
    Yoshinaga T
    Nihon Naibunpi Gakkai Zasshi; 1968 Oct; 44(7):741-9. PubMed ID: 4180485
    [No Abstract]   [Full Text] [Related]  

  • 16. [Normal histology of the beta-cells during insulin secretion].
    Bänder A
    Acta Diabetol Lat; 1968 Oct; 5 Suppl 1():417-35. PubMed ID: 4907224
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of islet-activating protein (IAP) upon insulin secretion from human pancreatic islets.
    Araki Y; Yoshida T; Nakamura N; Koyama K; Nakamura Y; Nakano K; Kondo M
    Endocrinol Jpn; 1981 Apr; 28(2):139-43. PubMed ID: 7030721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen.
    Sugawara K; Honda K; Reien Y; Yokoi N; Seki C; Takahashi H; Minami K; Mori I; Matsumoto A; Nakaya H; Seino S
    PLoS One; 2016; 11(10):e0164785. PubMed ID: 27764176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats.
    Kwon DY; Kim YS; Ahn IS; Kim DS; Kang S; Hong SM; Park S
    J Pharmacol Sci; 2009 Dec; 111(4):361-71. PubMed ID: 20019445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats.
    Inoue Y; Tanigawa K; Nakamura S; Xu G; Kawaguchi M; Kato Y; Tamura K
    Diabetes Res Clin Pract; 1995 Jan; 27(1):19-26. PubMed ID: 7781490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.